The WACC of Luminex Corp (LMNX) is 7.6%.
Range | Selected | |
Cost of equity | 6.8% - 9.5% | 8.15% |
Tax rate | 23.0% - 36.9% | 29.95% |
Cost of debt | 4.0% - 4.5% | 4.25% |
WACC | 6.4% - 8.8% | 7.6% |
Category | Low | High |
Long-term bond rate | 3.2% | 3.7% |
Equity market risk premium | 4.2% | 5.2% |
Adjusted beta | 0.86 | 1.01 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.8% | 9.5% |
Tax rate | 23.0% | 36.9% |
Debt/Equity ratio | 0.12 | 0.12 |
Cost of debt | 4.0% | 4.5% |
After-tax WACC | 6.4% | 8.8% |
Selected WACC | 7.6% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
LMNX | Luminex Corp | 0.12 | 0.57 | 0.52 |
ARYC | Arrayit Corp | 1428.99 | -1 | 0 |
BLI | Berkeley Lights Inc | 0.42 | 0.99 | 0.77 |
FLDM | Fluidigm Corp | 0.25 | 1.16 | 0.99 |
HBIO | Harvard Bioscience Inc | 2.65 | 1.92 | 0.67 |
INIS | International Isotopes Inc | 0.27 | 0.42 | 0.35 |
IPA.V | Immunoprecise Antibodies Ltd | 0.02 | -0.15 | -0.15 |
MRVI | Maravai LifeSciences Holdings Inc | 0.65 | 1.16 | 0.79 |
NSTG | NanoString Technologies Inc | 44.72 | 3.87 | 0.12 |
PACB | Pacific Biosciences of California Inc | 1.93 | 0.41 | 0.17 |
Low | High | |
Unlevered beta | 0.28 | 0.58 |
Relevered beta | 0.79 | 1.01 |
Adjusted relevered beta | 0.86 | 1.01 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for Luminex:
cost_of_equity (8.15%) = risk_free_rate (3.45%) + equity_risk_premium (4.70%) * adjusted_beta (0.86) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.